Clinical-stage biotechnology company Insilico Medicine (HKEX:3696) announced on Sunday that it has agreed an additional AI-empowered drug discovery collaboration with China Medical System Holdings Limited (CMS) (HKEX:867) (SGX:8A8) targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.

The two parties aim to jointly advance the co-development of the R&D programme by combining Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&D team and deep therapeutic expertise.

Insilico Medicine is eligible to receive up to approximately CNY1.2bn in milestone payments plus royalties.

The collaboration leverages both parties' complementary strengths across the full value chain, from drug discovery and clinical development to commercialisation.